A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting (Q37396252)

20 August 2017

A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting (English)

1 reference

multicenter clinical trial

20 August 2017

0 references

author

Stephen Fox

14

1 reference

20 August 2017

16

1 reference

20 August 2017

Richie Soong

13

0 references

Fabienne Grieu

4

object named as

Fabienne Grieu

1 reference

20 August 2017

5

Chelsee Hewitt

1 reference

20 August 2017

17

Barry Iacopetta

1 reference

20 August 2017

Vicki Whitehall

1

1 reference

20 August 2017

Kayla Tran

2

1 reference

20 August 2017

Aarti Umapathy

3

1 reference

20 August 2017

Tiffany-Jane Evans

6

1 reference

20 August 2017

Tuty Ismail

7

1 reference

20 August 2017

Wei Qi Li

8

1 reference

20 August 2017

Peter Collins

9

1 reference

20 August 2017

Paul Ravetto

10

1 reference

20 August 2017

Barbara Leggett

11

1 reference

20 August 2017

Manuel Salto-Tellez

12

1 reference

20 August 2017

Rodney J Scott

15

1 reference

20 August 2017

8 October 2009

1 reference

The Journal of Molecular Diagnostics

20 August 2017

1 reference

20 August 2017

11

1 reference

20 August 2017

6

1 reference

20 August 2017

543-552

1 reference

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

EGFR antagonists in cancer treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

The epidermal growth factor receptor as a target for colorectal cancer therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

Recurrent KRAS codon 146 mutations in human colorectal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

K-ras mutations and cetuximab in colorectal cancer.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2765753

Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67

2 September 2018

1 reference

12 December 2020

A case for integrated morphomolecular diagnostic pathologists

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

1 reference

12 December 2020

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

12 December 2020

10.2353/JMOLDX.2009.090057

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19815694

1 reference